Blood components produced from whole blood using the Atreus processing system

Abstract

From these in vitro data, blood components produced using the Atreus appear suitable for clinical use, with no clinically significant difference in the quality of components from WB held at ambient temperature overnight with or without active cooling.

Automated preparation of whole blood–derived platelets suspended in two different platelet additive solutions and stored for 7 days

“…There were previous validation studies performed in a controlled environment focused on analyzing PLT characteristics of PCs prepared from BCs obtained from Atreus 2C+ and either pooled manually and suspended in plasma or pooled with OrbiSac and suspended in PAS‐II (T‐Sol, Fenwal Europe sprl, Mont Saint Guibert, Belgium) . Other authors focused on analyzing RBCs, plasma, and BCs obtained with the Atreus 2C+ or PCs prepared from IPUs obtained with the Atreus 3C and stored in PAS‐II (SSP, MacoPharma) . Finally, in a routine environment, other authors focused on operational values and in vitro quality of blood components obtained with the Atreus 3C…”

“…First, the 2C protocol was designed to obtain 1 unit of red blood cells (RBCs), 1 unit of plasma, and 1 unit of residual white blood cells (WBCs) . Second, the 2C+ protocol was designed to obtain 1 unit of RBCs, one buffy coat (BC), and 1 unit of plasma . The obtained BCs can be pooled manually or automatically with either the OrbiSac (Terumo BCT) or the TACSI (Terumo BCT) to obtain a pooled platelet (PLT) concentrate (PC).…”

“…2,3 Second, the 2C+ protocol was designed to obtain 1 unit of RBCs, one buffy coat (BC), and 1 unit of plasma. 4 The obtained BCs can be pooled manually 5 or automatically with either the OrbiSac (Terumo BCT) 6 or the TACSI (Terumo BCT) 7,8 to obtain a pooled platelet (PLT) concentrate (PC). Finally, the most recent 3C protocol was developed to obtain 1 unit of RBCs, 1 unit of plasma, 1 interim PLT unit (IPU), and 1 unit of residual WBCs.…”

Processing and storage of blood components: strategies to improve patient safety

“…This dynamic process has benefits, as variations in centrifugation speed and detection systems are applied to optimize separation of components, resulting in higher yields. Such devices exist for whole blood, that is separated into red cells, plasma, and either a buffy coat 72,73 or an "intermediate platelet unit" 74,75 that can be pooled without a secondary centrifugation step. Alternatively, the device can process buffy coat pools into a PC.…”

Optimizing the blood component production process

“…© 2015 International Society of Blood Transfusion, ISBT Science Series (2016) 11 (Suppl. 1),[19][20][21][22][23][24][25] Optimizing WB processing 21…”